July 01, 2020
Block & Leviton LLP will represent a proposed class of shareholders in a suit in California federal court alleging drug developer Gossamer Bio Inc. violated federal securities laws by misleading investors about an asthma treatment it had in the works as it raised more than $317 million when it went public.